In this article, we introduced a screening of anti-fibrotic drugs focused on new genes. More precisely, we screened and cloned 127 new genes, reporting on a potential target gene and two promising drugs for fibrosis. Among 127 genes, hepatitis C virus nonstructural protein 5A transactivated protein 9 (NS5ATP9), which expression is significantly upregulated by tenofovir disoproxil fumarate (TDF)/tenofovir alafenamide fumarate (TAF), suppresses hepatic stellate cells (HSCs) and HFL1 cells (lung fibroblasts) activation. Therefore, we reported NS5ATP9 as a potential therapeutic target, and TDF/TAF as a new promising therapeutic strategy in fibrosis. These results elucidate mechanisms of disease and translate molecular techniques into clinical treatment.
NS5ATP9; gene; anti-fibrotic drugs; TDF; TAF; hepatocellular carcinoma; hepatitis C virus